ORTEXORTEX News
Tracking FROG? Get live short interest, options flow, and signals on ORTEX.Sign up free →
FR
Earnings PreviewFROG

JFrog Heads Into Earnings on a Wave of Analyst Upgrades

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 7 Aug 2026, 04:03

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

FROG reports Q2 results today against a backdrop of unusually broad analyst optimism — with nearly every covering firm having lifted targets in the past six weeks, even as Morgan Stanley stepped back from its bullish stance just before the print.

The analyst move is the clearest signal into this earnings event. JPMorgan, BTIG, Truist, Guggenheim, UBS, Canaccord, and Cantor Fitzgerald all raised price targets over the past month — most from the high $70s or low $80s into the $95–$110 range. The consensus mean now sits at $94.38, comfortably above the current price of $83.04, implying roughly 14% upside. The one notable dissent came from Morgan Stanley, which downgraded FROG to Equal-Weight on July 21 while simultaneously lifting its target to $95 — a signal that at least one bellwether firm views the recent rally as having priced in much of the good news. That tension between broad target inflation and a high-profile rating cut sets up the debate neatly: bulls point to JFrog's expanding AI infrastructure story and strong DevOps platform positioning, while bears flag a competitive and evolving DevSecOps market, heavy reliance on the US, and a valuation that remains stretched at roughly 76x trailing earnings.

Short interest has actually been unwinding ahead of the print, which argues against a crowded bear trade. SI has fallen nearly 4.5% over the past week to 7.2% of the free float — down sharply from a peak of around 10% in mid-July. Borrow conditions reinforce that picture: availability is effectively wide open at close to 1,000%, meaning there is roughly ten times more stock available to lend than is currently borrowed, and the cost to borrow has eased to just 0.46%, the lowest level in over a month. Options positioning adds a further wrinkle — the put/call ratio of 0.21 is essentially flat with its 20-day average of 0.21, and sits near the 52-week low end of the range, suggesting call buyers remain in control and there is minimal hedging pressure entering the release.

One complicating note from the institutional side: the company's own co-founders and insiders were net sellers through mid-July. Co-founder and CTO Yoav Landman sold roughly $3.9 million of stock on July 17 alone, while Lead Independent Director Yoseph Sela sold approximately $2.2 million the prior day. This came when the stock was trading in the mid-to-high $80s — around the same price range as today. That insider activity does not indicate panic, but it does suggest insiders were comfortable locking in gains at current levels. BlackRock's recent addition of over 5.6 million shares as of June 30 provides a counterweight, making the index giant the largest disclosed holder at 6% of shares.

The previous earnings cycle is also worth noting: FROG jumped 21% on the day of its May print and held most of that gain over the following week, a reaction that likely explains both the analyst target resets and the subsequent pullback of roughly 15% over the past month. Today's print tests whether the company can sustain the growth trajectory that justified that re-rating — or whether the May beat was the high-water mark that the Morgan Stanley downgrade already anticipated.

Stocks in this article

See the live data behind this article on ORTEX.

Open FROG on ORTEX →

How this article was generated

Generated
7 Aug 2026, 04:25
Data as of
7 Aug 2026, 04:03
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notes

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.